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Abstract: Background: The effect of dietary fat intake on the metabolic syndrome (MetS) and in
turn on cardiovascular disease (CVD) remains unclear in individuals at high CVD risk. Objective:
To assess the association between fat intake and MetS components in an adult Mediterranean
population at high CVD risk. Design: Baseline assessment of nutritional adequacy in participants
(n = 6560, men and women, 55–75 years old, with overweight/obesity and MetS) in the PREvención
con DIeta MEDiterránea (PREDIMED)-Plus randomized trial. Methods: Assessment of fat intake
(total fat, monounsatured fatty acids: MUFA, polyunsaturated fatty acids: PUFA, saturated fatty acids:
SFA, trans-fatty acids: trans-FA, linoleic acid, α-linolenic acid, andω-3 FA) using a validated food
frequency questionnaire, and diet quality using 17-item Mediterranean dietary questionnaire and fat
quality index (FQI). Results: Participants in the highest quintile of total dietary fat intake showed
lower intake of energy, carbohydrates, protein and fiber, but higher intake of PUFA, MUFA, SFA, TFA,
LA, ALA andω-3 FA. Differences in MetS components were found according to fat intake. Odds (5th
vs. 1st quintile): hyperglycemia: 1.3–1.6 times higher for total fat, MUFA, SFA andω-3 FA intake; low
high-density lipoprotein cholesterol (HDL-c): 1.2 higher for LA; hypertriglyceridemia: 0.7 lower for
SFA andω-3 FA intake. Conclusions: Dietary fats played different role on MetS components of high
CVD risk patients. Dietary fat intake was associated with higher risk of hyperglycemia.
Keywords: fatty acids; dietary fat; fat intake; Mediterranean diet; cardiovascular disease risk
1. Introduction
Obesity and the ensuing metabolic syndrome (MetS) are becoming an epidemic. If recent secular
trends continue unabated, up to 20% of the world’s adult population (1.2 billion individuals) is expected
to be obese by 2030. The prevalence of type 2 diabetes mellitus (T2DM) and cardiovascular disease
(CVD) are also expected to increase by 54% and 22%, respectively [1–4].
In an effort to tackle the problem of obesity, and in turn cardiovascular risk, nutritional guidelines
recommended a global limit on total fat intake, inevitably resulting in an increased intake of simple
carbohydrates and decreased intake of healthy unsaturated fatty acids (UFA) [5]. Dietary UFA may
prevent the development of metabolic diseases such as T2DM, and reduce cardiovascular events [6].
Moreover, the presumed relationship between dietary saturated fatty acids (SFA) and an increased risk
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of coronary heart disease (CHD) or CVD may depend on the complexity of these fatty acids and the
food matrix in which they are present [7].
Evidence currently available resulting from the dietary fat interventions does not support the
current dietary fat guidelines [8]. In 2015, the Dietary Guidelines Advisory Committee emphasized the
importance of healthful, food-based diet patterns, revisiting the role of fat in health [9].
The Mediterranean diet (MedDiet) is characterized by high intakes of plant foods (fruits, vegetables,
legumes, nuts, and whole grains) and olive oil as the principal source of dietary lipids [10]. This dietary
pattern seems to ameliorate metabolic risk factors defining the MetS [11] (and reduce the incidence of
cardiovascular events, breast cancer, and T2DM compared with any other diet [12,13].
The PREvención con DIeta MEDiterránea (PREDIMED)-Plus study provides a unique opportunity
to assess the association between fat intake and MetS components in an adult Mediterranean population
at high CVD risk.
2. Methods
2.1. Study Design
This research represents a cross-sectional study on baseline data of the PREDIMED-Plus trial.
PREDIMED-Plus study is an ongoing 6-year multicenter, parallel-group, randomized trial conducted
in 23 Spanish recruiting centers to evaluate the effect of an intensive weight loss program based on
an energy-restricted traditional Mediterranean diet (erMedDiet), physical activity promotion, and
behavioral support on hard cardiovascular events, in comparison with an usual care intervention only
with energy-unrestricted MedDiet (control group) and any advice to increase physical activity. The
PREDIMED-Plus study protocol is fully described in a publication by Martínez-González et al. [14] and
available at http://predimedplus.com/. The trial was registered in 2014 at the International Standard
Randomized Controlled Trial (ISRCT; http://www.isrctn.com/ISRCTN89898870) with number 89898870.
2.2. Participants, Recruitment, and Randomization
Eligible participants were community-dwelling adults men aged between 55 and 75 years and
women between 60 and 75 years, without documented history of CVD at enrollment, who were
overweight or obese (body mass index [BMI] ≥27 and <40 kg/m2) and meeting at least 3 criteria for the
MetS according to the updated harmonized definition of the International Diabetes Federation and the
American Heart Association and National Heart, Lung and Blood Institute [15]: Abdominal obesity for
European individuals (WC ≥88 cm in women and ≥102 cm in men), hypertriglyceridemia (≥150 g/dL)
or drug treatment for high plasma triglycerides (TG) concentrations, low high-density lipoprotein
cholesterol (HDL-cholesterol; ≤50 mg/dL in women and ≤40 mg/dL in men), high blood pressure
(systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg or antihypertensive drug
treatment), or high fasting plasma glucose (≥100 mg/dL) or drug treatment for T2DM.
From 5 September 2013 to 31 October 2016, a total of 6874 participants were recruited in 23 Spanish
centers (universities, hospitals, and research institutes).
The present analysis included 6560 subjects (3387 men and 3173 women (Figure 1) were included).
We excluded those participants (n = 314) recording extreme total energy intakes (<500 or >3500 kcal/day
in women or <800 or >4000 kcal/day in men) [16]. We also excluded participants who did not respond
to all the physical activity questionnaires (n = 14) and participants reporting outliers for total physical
activity expressed as metabolic equivalents of task [METs·min/week (at 3 or more standard deviations
[SD] from the mean for each sex)].
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2.3. Ethics
All participants provided written informed consent, and the study protocol and procedures
were approved according to the ethical standards of the Declaration of Helsinki by all the
participating institutions.
2.4. Dietary Assessment
Registered dietitians collected data on dietary intake at baseline with a semiquantitative 143-item
food frequency qu stionnaire (FFQ), assessing dietary h bits over the previous 12 months, repeatedly
validated in Spain [17]. Detailed information about the development, rep oducibility, and validity of
FFQ in the PREDIMED cohort has been previously reported [17–19]. For each item, a typical portion
size was included and consumption frequencies were registered in 9 categories that ranged from
“never or almost n ver” to “≥6 times/ ay”. Energy and n trient intakes were calculated as frequency
multiplied by nutrient composition of specified portion size for each food item, using a computer
program based on available information in fo d composition tables [20–23]. The selected frequency
ite was conve ted to a daily int ke. For exa ple, if a response was 5–6 times a week, it was conv rt
to 0.78 servings per day (5.5 week/7 da s) [19]. ach FFQ food item, we e timated the average
amount of food consumed (grams), the averag total energy intake, nd the average intak of a set of
macro-and micr nutrients by mputing the ean of the v lues for the individual foo s assigned to
that item [24].
We also considered the total nutrient intake, the average intake of micronutrients from dietary
supplements declared by participants in the FFQ.
2.5. Determination of Fat Intake
Dietary intake of total fat and fatty acids: Monounsaturated (MUFA), polyunsaturated (PUFA),
and satur ted (SFA), trans-fat y acid (TFA), linoleic acid (LA), α-linolenic acid (ALA), and marineω-3
fatty cid (ω-3 FA) we e estimated.
On the other hand, the fat quality index (FQI) was calculated as previously described [16]. Briefly,
the FQI was calculated using the ratio (MUFA + PUFA)/(SFA + TFA) as a continuous variable.
Participants were also a ministered 17-item Mediterranean dietary questi naire, a modified
version of the previously vali ated questionna r used in the PREDIMED trial [25]. Compliance with
each f the 17 food habits reflecting an erMedDiet was scored with 1 point and 0 p ints other ise.
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Therefore, a score ranging from 0–17 points, with 0 meaning no adherence and 17 meaning maximum
adherence, was developed.
2.6. Physical Activity
Physical activity was measured using the Rapid Assessment of Physical Activity Questionnaires
(RAPA-1 and RAPA-2) [26] and the validated Minnesota-REGICOR (Registre Gironí del Cor) Short
Physical Activity questionnaire [27–29]. Metabolic Equivalent of tasks (MET) are calculated by
multiplying the intensity (showed by the MET-score) and the duration spent on that activity (measured
in minutes). The intensity was assigned based on the compendium of physical activity [30]. Detailed
information about the development and reproducibility has been reported [31].
2.7. Anthropometric and Blood Pressure Measurements
Anthropometric variables were measured by trained personnel according to the PREDIMED-Plus
protocol. Weight and height were measured with high-quality electronic calibrated scales and a
wall-mounted stadiometer, respectively. BMI was calculated as weight in kilograms divided by
the square of height in meters. Waist circumference (WC) was measured halfway between the last
rib and the iliac crest by using an anthropometric tape. Blood pressure was measured in triplicate
with a validated semi-automatic oscillometer (Omron HEM-705CP) after 5 min of rest in-between
measurements while the participant was in a seated position. All anthropometric variables were
determined in duplicate, except for blood pressure (in triplicate).
2.8. Blood Collection and Analysis
Samples of fasting blood and urine were also collected after an overnight fast at baseline.
Biochemical analyses were performed on fasting plasma glucose, total cholesterol, low high-density
lipoprotein cholesterol (HDL-c,) and triglyceride (TG) concentrations in local laboratories using
standard enzymatic methods.
2.9. Other Health Outcomes
At the baseline visit, additional information related to sociodemographic and lifestyle aspects
(education level, civil status, smoking habits, alcohol intake, physical activity, individual and family
medical history, and current medication use) was collected.
2.10. Statistical Analyses
Analyses were performed with the SPSS statistical software package version 25.0 (SPSS Inc.,
Chicago, IL, USA). We used the PREDIMED-Plus baseline database generated in August 2017. Overall,
8 nutrients were examined (total fat, MUFA, PUFA, SFA, TFA, LA, ALA and ω-3 FA). Following
standard procedures, nutrient intakes were energy-adjusted using the residual method [32,33] and
then converted into quintiles. Qualitative variables were expressed as percentages and quantitative
variables were expressed as means and SD. Pearson’s chi-square tests and analysis of variance
(ANOVA) (for categorical and continuous variables, respectively) were used to compare differences
across quintile groups. We used the Bonferroni method to test multiple comparisons across quintile
groups. Logistic regression analyses with the calculation of corresponding odds ratio (OR) and the
95% confidence interval (95% CI) were also used to assess the association between MetS components
and quintiles of dietary fat and fat subtypes. Results were adjusted for sex, age (continuous variable),
BMI (continuous variable), energy intake (continuous variable), alcohol intake (continuous variable),
adherence to the MedDiet (continuous variables), total physical activity (continuous variable, expressed
as MET·min/week), smoking habit (categorized variable: Current, former and never) and education
level (categorized variable: Primary, secondary, university, or graduate) to control for potential
confounders. Results were considered statistically significant if p-value (2 tailed) <0.05.
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3. Results
The general characteristics of the study population across quintiles of total and several subtypes
of dietary fat intake are shown in Table 1. The percentage of energy from total dietary fat of the
participants ranged from 30.5 (SD: 2.9) in the lowest to 48.5 (SD: 3.3) in the highest quintile (mean:
39.4%, SD: 6.5). Specifically, women had significantly higher intakes of total fat, PUFA, SFA, LA and
ALA, but lower in the highest quintile of TFA intake. BMI was significantly lower in the highest
vs. lowest quintile of total PUFA (0.3 ± 0.13 kg/m2, p < 0.001), LA (0.3 ± 0.13 kg/m2, p = 0.020) and
ALA (0.6 ± 0.13 kg/m2, p < 0.001). Conversely, BMI was significantly higher in the highest quintiles of
total fat and SFA. Mean physical activity (expressed as METs·min/week) was significantly higher in
the highest quintile of MUFA, PUFA, ALA and ω-3 FA intakes, but lower in the highest quintile of
SFA and TFA intakes. Statistical significant differences in education level were also found between
quintile groups of total fat, MUFA, SFA, TFA, LA, and ω-3 FA intake. Statistical significant differences
in smoking habits were also found between quintile groups of PUFA, SFA, TFA, ALA, andω-3 FA.
The nutrient intake and food consumption of the participants as per quintiles of total and several
subtypes of dietary fat were also assessed (Tables 2 and 3). Participants in the highest quintile of total
dietary fat intake had significantly lower intakes of energy, carbohydrates, protein, and fiber, but higher
intakes of all subtypes of fat (PUFA, MUFA, SFA, TFA, LA, ALA, and ω-3 FA). Participants in the
highest quintiles of PUFA, LA, and ALA intake had lower TFA and cholesterol intakes but higher fiber
intake (except for ALA quintiles). Fiber intake was also higher in participants in the highest quintile of
ω-3 FA intake. Participants in the highest quintile ofω-3 FA and SFA intake had significantly higher
intake of protein and cholesterol. Cholesterol intake was also higher in participants in the highest
quintile of TFA. FQI increased significantly with increasing quintiles of total and all subtypes of dietary
intake except for SFA and TFA.
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Table 1. Lifestyle characteristics and Metabolic Syndrome components according to total dietary fat and specific types of fat (g/day).
Total Fat MUFAs PUFAs SFAs
Q1 Q5 p Value Q1 Q5 p Value Q1 Q5 p Value Q1 Q5 p Value
Participants, n 1294 1291 1312 1312 1312 1312 1312 1312
Age, years 65.1 ± 5.0 64.7 ± 4.9 0.164 65.1 ± 5.0 64.8 ± 4.8 0.088 64.7 ±5.0 * 65.3 ± 4.9 * 0.016 65.2 ± 5.0 * 64.5 ± 5.0 * <0.001
Women, % 43.4 48.5 <0.001 45.0 48.8 0.094 40.5 49.2 <0.001 42.5 46.7 <0.001
BMI, kg/m2 32.4 ± 3.4 32.8 ± 3.5 NS 0.005 32.4 ± 3.4 32.7 ± 3.6 0.226 32.6 ± 3.4 * 32.3 ± 3.4 * <0.001 32.3 ± 3.3 * 32.8 ±3.5 * <0.001
Smoking habit, %
Current 11.6 12.0
0.820
11.1 12.0
0.446
14.1 11.5
0.002
11.2 12.5
0.021Former 44.0 44.6 42.2 44.9 47.1 41.7 46.7 45.2
Never 44.5 43.4 46.7 43.1 38.8 46.8 42.1 42.3
Education, %
Primary 52.3 42.6
<0.001
52.8 44.5
0.001
46.2 48.7
0.268
50.3 40.3
<0.001Secondary 28.3 30.3 27.7 29.6 30.6 28.2 27.8 34.7
University or graduate 19.4 27.1 19.5 25.9 23.2 23.1 21.9 25.0
Total physical activity, n † 1213 1225 1226 1240 1225 1251 1235 1248
Total physical activity,
MET·min/week † 2394 ± 2024 2440 ± 1876 0.912 2396 ± 1965 * 2486 ± 1883 * 0.027 2322 ± 2019
2529 ± 1875
NS 0.025 2628 ± 2042 * 2281 ± 1918 * <0.001
Males 2796 ± 2268 2632 ± 2029 0.233 2745 ± 2177 2744 ± 2029 0.146 2674 ± 2231 2838 ± 2088 0.366 3053 ± 2256 * 2572 ± 2163 * 0.001
Females 1868 ± 1500 * 2233 ± 1672 * 0.004 1970 ± 1569 * 2213 ± 1673 * 0.005 1799 ± 1513 * 2205 ± 1559 * <0.001 2039 ± 1518 1950 ± 1531 0.458
MetS components, %
High blood pressure 93.0 91.7 0.328 92.5 91.3 0.300 92.8 92.0 0.724 92.5 91.3 0.495
Hyperglycaemia 73.9 80.3 <0.001 74.0 80.0 <0.001 73.3 75.6 0.014 73.2 78.3 0.032
Hypertriglyceridemia 58.7 56.6 0.139 57.0 56.0 0.889 56.8 55.2 0.111 57.9 53.4 0.120
Low HDL-cholesterol 38.7 44.4 0.004 40.4 44.7 0.171 40.9 46.3 0.015 40.2 42.1 0.068
Abdominal obesity 95.2 96.7 0.180 95.4 96.6 0.317 95.6 96.6 0.657 95.5 96.4 0.380
Males 92.0 94.3 0.387 92.2 94.0 0.386 93.1 94.2 0.704 92.6 93.8 0.503
Females 99.5 99.4 0.944 99.3 99.4 0.453 99.2 99.2 0.543 99.5 99.3 0.990
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Table 1. Cont.
Trans FA Linoleic acid Linolenic acid ω-3 FA
Participants, n 1312 1312 1312 1312 1312 1312 1312 1312
Age, years 65.8 ± 4.7 * 64.0 ± 5.1 * <0.001 64.6 ± 5.0 * 65.4 ± 4.9 * 0.001 63.9 ± 5.0 * 65.6 ± 4.8 * <0.001 65.1 ± 5.0 65.1 ± 4.8 0.345
Women, n (%) 60.9 37.6 <0.001 40.2 48.2 <0.001 29.9 56.6 <0.001 47.6 51.2 0.217
BMI, kg/m2 32.3 ± 3.4 32.6 ± 3.5 0.074 32.6 ± 3.4 32.3 ± 3.3 NS 0.020 32.7 ± 3.4 * 32.1 ± 3.3 * <0.001 32.7 ± 3.4 32,5 ± 3.4 0.387
Smoking habit, n (%)
Current 8.9 14.0
<0.001
14.0 12.2
0.007
16.7 9.5
<0.001
14.4 10.3
0.003Former 39.7 47.0 47.1 41.8 49.6 39.4 42.4 45.1
Never 51.4 39.0 39.0 46.0 33.8 51.1 43.2 44.6
Education, n (%)
Primary 57.0 41.3
<0.001
44.1 50.5
0.003
46.6 50.1
0.286
54.2 47.2
<0.001Secondary 24.6 31.6 30.8 28.1 29.9 27.6 27.4 27.8
University or graduate 18.4 27.1 25.2 21.4 23.5 22.3 18.3 25.0
Total physical activity, n † 1248 1230 1229 1249 1216 1251 1237 1253
Total physical activity,
MET·min/week † 2572 ± 1924 2373 ± 1977 0.075 2445 ± 2098 2499 ± 1884 0.130 2454 ± 2099 * 2621 ± 1961 * 0.002 2227 ± 1952 * 2673 ± 2038 * <0.001
Males 3107 ± 2208 * 2580 ± 2168* <0.001 2801 ± 2332 2852 ± 2095 0.491 2695 ± 2241 * 3080 ± 2230 * 0.015 2657 ± 2168 2983 ± 2341NS 0.048
Females 2225 ± 1624 * 2027 ± 1550 * 0.006 1908 ± 1539 2114 ± 1534 0.191 1852 ± 1541 * 2262 ± 1636 * <0.001 1744 ± 1541 * 2372 ± 1639 * <0.001
MetS components, n (%)
High blood pressure 91.9 92.3 0.108 92.9 92.0 0.313 92.9 91.6 0.566 91.8 91.5 0.068
Hyperglycaemia 76.2 75.2 0.232 73.4 75.2 0.047 74.1 75.8 0.373 74.0 79.0 0.020
Hypertriglyceridemia 55.2 55.6 0.611 55.6 56.4 0.847 57.2 53.2 0.186 59.1 50.8 <0.001
Low HDL-cholesterol 43.5 42.2 0.863 39.9 47.0 <0.001 41.5 44.7 0.586 45.8 41.1 0.147
Abdominal obesity 95.9 95.7 0.360 95.6 96.3 0.850 94.4 97.0 0.009 95.8 97.1 0.179
Males 90.6 93.7 0.170 93.1 93.5 0.948 92.2 94.0 0.414 92.6 94.7 0.338
Females 99.2 99.2 0.587 99.2 99.2 0.479 99.7 99.2 0.343 99.4 99.4 0.210
Abbreviations: BMI, body mass index; FA, fatty acids; HDL-cholesterol, high density lipoprotein cholesterol; MetS, Metabolic Syndrome; MET, metabolic equivalent of task; MUFAs
monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; SFAs, saturated fatty acids. All values are means ± SDs unless otherwise indicated. All quartiles were included in
theanalysis. Pearson’s chi-square test was used for categorical variables, and 1-factor ANOVA was used for continuous variables. * p < 0.05 for between-group changes, after adjustment for
multiple comparisons with the Bonferroni method. NS No statistical significance after post hoc test. † Participants who not responded the physical activity questionnaires and participants
reporting outliers for total physical activity expressed as MET·min/week (at 3 or more standard deviations from the mean) were excluded from the analysis (i.e., 154 men and 196 women).
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Table 2. Nutrient intake according to total dietary fat and specific types of fat (g/day).
Total Fat MUFAs PUFAs SFAs
Q1 Q5 p Value Q1 Q5 p Value Q1 Q5 p Value Q1 Q5 p Value
Participants, n 1294 1291 1312 1312 1312 1312 1312 1312
Energy intake, kcal/day 2446 ± 579 * 2432 ± 509 * <0.001 2415 ± 594 * 2417 ± 516 * <0.001 2539 ± 534 * 2498 ± 517 * <0.001 2532 ± 533 * 2456 ± 551 * <0.001
Carbohydrate intake, % total
energy 48.6 ± 5.4 * 33.3 ± 4.3 * <0.001 48.0 ± 5.6 * 34.1 ± 4.9 * <0.001 45.7 ± 6.5 * 37.7 ± 6.2 * <0.001 46.3 ± 6.3 * 36.0 ± 5.7 * <0.001
Protein intake, % total
energy 16.7 ± 3.0 * 15.9 ± 2.5 * <0.001 17.0 ± 3.0 * 15.7 ± 2.4 * <0.001 16.3 ± 2.7 * 16.2 ± 2.7 * <0.001 15.9± 2.7 * 16.7 ± 2.7 * <0.001
Fat intake, % total energy 30.5 ± 2.9 * 48.5 ± 3.3 * <0.001 31.4 ± 3.9 * 47.6 ± 4.1 * <0.001 33.7 ± 5.1 * 43.7 ±5.9 * <0.001 33.5 ± 5.1 * 44.8 ± 5.5 * <0.001
PUFA, % total energy 5.0 ± 1.3 * 7.8 ± 2.0 * <0.001 5.5 ± 1.9 * 7.4 ± 1.6 * <0.001 4.3 ± 0.5 * 9.1 ± 1.5 * <0.001 6.0 ± 1.8 * 6.4 ± 1.8 * <0.001
MUFA, % total energy 14.8 ± 2.2 * 26.2 ± 3.5 * <0.001 14.3 ± 1.8 * 26.9 ± 2.9 * <0.001 17.0 ± 3.2 * 22.2 ± 5.0 * <0.001 17.5 ± 4.1 * 22.7 ± 4.4 * <0.001
SFA, % total energy 8.2 ± 1.5 * 11.7 ± 1.9 * <0.001 8.7 ± 1.8 * 11.0 ± 1.9 * <0.001 9.6 ± 2.2 * 10.0 ± 1.8 * <0.001 7.5 ± 0.9 * 12.8 ± 1.4 * <0.001
Trans FA, g/day 0.52 ± 0.3 * 0.71 ± 0.5 * <0.001 0.57 ± 0.4 * 0.63 ± 0.4 * <0.001 0.66 ± 0.4 * 0.59 ± 0.4 * <0.001 0.39 ± 0.3 * 0.94 ± 0.5 * <0.001
Linoleic acid, g/day 11.1 ± 4.5 * 17.4 ± 6.4 * <0.001 12.0 ± 5.7 * 16.3 ± 5.4 * <0.001 9.8 ± 3.1 * 20.8 ± 5.5 * <0.001 13.7 ± 5.4 * 14.3 ± 5.8 * <0.001
Linolenic acid, g/day 1.2 ± 0.6 * 1.8 ± 0.8 * <0.001 1.3 ± 0.7 * 1.7 ± 0.7 * <0.001 1.1 ± 0.3 * 2.3 ± 0.8 * <0.001 1.4 ± 0.7 * 1.6 ± 0.6 * <0.001
ω-3 FA, g/day 1.48 ± 0.9 * 1.65 ± 0.9 * <0.001 1.52 ± 0.9 * 1.61 ± 0.8 * 0.001 1.39 ± 0.8 * 1.72 ± 0.89 * <0.001 1.59 ± 0.9 1.55 ± 0.8 0.360
FQI, score 2.4 ± 0.5 * 3.0 ± 0.7 * <0.001 2.29 ± 0.5 * 3.15 ± 0.7 * <0.001 2.26 ± 0.5 * 3.16 ± 0.7 * <0.001 3.12 ± 0.7 * 2.24 ± 0.4 * <0.001
Cholesterol (mg/day) 365 ± 113 * 399 ± 119 * <0.001 378 ± 122 383 ± 115 0.182 394 ± 134 * 381 ± 111 * <0.001 346 ± 106 * 438 ± 125 * <0.001
Fibre intake (g/day) 29 ± 10.0 * 23.8 ± 7.7 * <0.001 27.9 ± 9.2 * 25.0 ± 8.4 * <0.001 26.6 ± 9.0 * 28.3 ± 9.1 * <0.001 31.2 ± 10.3 * 22.6 ± 7.2 * <0.001
Trans FA Linoleic acid Linolenic acid ω-3 FA
Participants, n 1312 1312 1312 1312 1312 1312 1312 1312
Energy intake, kcal/day 2001 ± 467 * 2739 ± 522 * <0.001 2541 ± 528 * 2489 ± 518 * <0.001 2894 ± 419 * 2271 ± 517 * <0.001 2176 ± 549 * 2517 ± 520 * <0.001
Carbohydrate intake, % total
energy 46.3 ± 6.3 * 36.0 ± 5.7 * <0.001 44.9 ± 6.7 * 38.0 ± 6.2 * <0.001 44.4 ± 6.5 38.0 ± 6.4 <0.001 43.0 ± 7.2 * 39.1 ± 6.3 * <0.001
Protein intake, % total
energy 17.1 ± 3.2 * 16.0 ± 2.5 * <0.001 16.8 ± 3.0 * 15.9 ± 2.5 * <0.001 15.2 ± 2.2 17.2 ± 2.9 <0.001 15.5 ± 2.8 * 17.8 ± 2.6 * <0.001
Fat intake, % total energy 38.1 ± 7.2 * 40.9 ± 6.0 * <0.001 34.0 ± 5.4 * 43.7 ± 5.9 * <0.001 34.0 ± 5.4 43.7 ± 5.9 <0.001 38.5 ± 7.0 * 40.1 ± 6.2 * <0.001
PUFA, % total energy 6.4 ± 2.0 * 6.3 ± 1.7 * 0.044 4.4 ± 0.6 * 9.1 ± 1.6 * <0.001 5.4 ± 1.5 8.5 ± 1.7 <0.001 6.0 ± 2.0 * 6.8 ± 1.8 * <0.001
MUFA, % total energy 20.6 ± 5.3 20.6 ± 4.2 0.581 17.1 ± 3.3 * 22.2 ± 5.0 * <0.001 18.2 ± 3.8 21.8 ± 5.0 <0.001 20.1 ± 4.9 * 20.7 ± 4.5 * 0.003
SFA, % total energy 7.5 ± 0.9 * 12.8 ± 1.4 * <0.001 9.7 ± 2.3 * 10.0 ± 1.8 * <0.001 9.4 ± 1.8 9.9 ± 2.1 <0.001 9.8 ± 2.1 9.9 ± 1.9 0.168
Trans FA, g/day 0.18 ± 0.1 * 1.18 ± 0.4 * <0.001 0.65 ± 0.4 * 0.62 ± 0.4 * <0.001 0.70 ± 0.4 * 0.52 ± 0.4 * <0.001 0.57 ± 0.4 * 0.58 ± 0.4 * 0.015
Linoleic acid, g/day 11.4 ± 5.1 * 16.1 ± 6.1 * <0.001 9.6 ± 2.9 * 20.9 ± 5.4 * <0.001 14.2 ± 5.3 * 17.5 ± 5.7 * <0.001 12.5 ± 5.8 * 14.4 ± 5.6 * <0.001
Linolenic acid, g/day 1.3 ± 0.7 * 1.7 ± 0.7 * <0.001 1.1 ± 0.3 * 2.2 ± 0.8 * <0.001 1.2 ± 0.3 * 2.3 ± 0.8 * <0.001 1.2 ± 0.7 * 1.7 ± 0.7 * <0.001
ω-3 FA, g/day 1.54 ± 0.9 * 1.56 ± 0.8 * 0.170 1.62 ± 0.9 * 1.58 ± 0.9 * 0.009 1.56 ± 0.8 * 1.69 ± 0.9 * <0.001 0.63 ± 0.2 * 2.92 ± 0.4 * <0.001
FQI, score 3.25 ± 0.7 * 2.29 ± 0.5 * <0.001 2.25 ± 0.5 * 3.14 ± 0.7 * <0.001 2.51 ± 0.5 * 3.08 ± 0.7 * <0.001 2.67 ± 0.7 * 2.78 ± 0.6 * <0.001
Cholesterol (mg/day) 300 ± 90 * 461 ± 124 * <0.001 406 ± 135 * 376 ± 111 * <0.001 427 ± 140 * 361 ± 106 * <0.001 305 ± 100 * 445 ± 116 * <0.001
Fibre intake (g/day) 26.2 ± 9.0 25.8 ± 8.4 0.784 27.1 ± 9.1 * 27.6 ± 9.1 * <0.001 28.1 ± 9.0 * 28.0 ± 9.2 * <0.001 23.1 ± 8.2 * 28.7 ± 9.1 * <0.001
Abbreviations: FA, fatty acids; FQI, fat quality index; MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; SFAs, saturated fatty acids. All values are means ± SDs
unless otherwise indicated. All quartiles were included in the analysis. Pearson’s chi-square test was used for categorical variables, and 1-factor ANOVA was used for continuous variables.
* p < 0.05 for between-group changes, after adjustment for multiple comparisons with the Bonferroni method.
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Table 3. Food consumption according to total dietary fat and specific types of fat (g/day).
Total Fat MUFAs PUFAs SFAs
Q1 Q5 p Value Q1 Q5 p Value Q1 Q5 p Value Q1 Q5 p Value
Participants, n 1294 1291 1312 1312 1312 1312 1312 1312
Dietary items
Fruits, g/day 420 ± 259 * 305 ± 170 * <0.001 404 ± 239 * 327 ± 183 * <0.001 383 ± 238 * 370 ± 205 * <0.001 444 ± 258 * 289 ± 172 * <0.001
Vegetables, g/day 333 ± 149 * 310 ± 128 * <0.001 331 ± 148 * 320 ± 132 * 0.001 319 ± 144 * 340 ± 138 * <0.001 356 ± 154 * 292 ± 129 * <0.001
Legumes, g/day 22 ± 13 * 19 ± 10 * <0.001 22 ± 13 * 20 ± 10 * <0.001 20 ± 12 * 21 ± 11 * 0.004 23 ± 13 * 19 ± 10 * <0.001
Olive oil, g/day 27 ± 13 * 55 ± 14 * <0.001 23 ± 10 * 57 ± 13 * <0.001 36 ± 15 * 41 ± 19 * <0.001 38 ± 16 * 43 ± 18 * <0.001
Nuts, g/day 10 ± 12 * 22 ± 23 * <0.001 10 ± 12 * 24 ± 24 * <0.001 5 ± 6 * 34 ± 23 * <0.001 17 ± 20 * 13 ± 15 * <0.001
Total fish, g/day 97 ± 49 * 105 ± 47 * <0.001 99 ± 50 103 ± 46 NS 0.022 94 ± 46 * 107 ± 48 * <0.001 104 ± 50 * 99 ± 47 * 0.017
Total cereals, g/day 203 ± 95 * 110 ± 52 * <0.001 190 ± 94 * 118 ± 59 * <0.001 196 ± 91 * 138 ± 69 * <0.001 208 ± 93 * 118 ± 60 * <0.001
Dairy products, g/day 402 ± 226 * 302 ± 177 * <0.001 406 ± 220 * 292 ± 175 * <0.001 418 ± 223 * 324 ± 197 * <0.001 348 ± 226 * 267 ± 202 * <0.001
Total meat, g/day 136 ± 57 * 156 ± 61 * <0.001 140 ± 59 * 148 ± 58 * <0.001 152 ± 59 * 146 ± 59 * <0.001 130 ± 52 * 172 ± 62 * <0.001
Cookies, g/day 30 ± 35 * 25 ± 27 * <0.001 32 ± 35 * 23 ± 25 * <0.001 36 ± 39 * 25 ± 27 * <0.001 23 ± 27 * 35 ± 35 * <0.001
Alcohol, g/day 15 ± 20 * 8 ± 11 * <0.001 13 ± 18 * 9 ± 12 * <0.001 16 ± 20 * 9 ± 13 * <0.001 16 ± 20 * 9 ± 12 * <0.001
17-item MedDiet Q, score 8.27 ± 2.62 * 8.56 ± 2.69 * 0.005 8.19 ± 2.67 * 8.88 ± 2.61 * <0.001 7.68 ± 2.57 * 9.07 ± 2.73 * <0.001 9.09 ± 2.67 * 7.65 ± 2.54 * <0.001
Trans FA Linoleic acid Linolenic acid ω-3 FA
Participants, n 1312 1312 1312 1312 1312 1312 1312 1312
Dietary items
Fruits, g/day 379 ± 207 * 334 ± 198 * <0.001 390 ± 239 * 365 ± 206 * <0.001 383 ± 237 * 378 ± 216 * <0.001 321 ± 209 * 392 ± 229 * <0.001
Vegetables, g/day 332 ± 137 * 309 ± 134 * <0.001 335 ± 150 * 330 ± 137 * 0.001 326 ± 143 * 347 ± 139 * <0.001 269 ± 125 * 377 ± 145 * <0.001
Legumes, g/day 20 ± 12 21 ± 11 0.730 21 ± 12 21 ± 11 0.061 22 ± 12 * 21 ± 11 * <0.001 19 ± 11 * 23 ± 12 * <0.001
Olive oil, g/day 39 ± 17 40 ± 18 0.154 35 ± 15 * 42 ± 19 * <0.001 42 ± 17 * 39 ± 17 * <0.001 37 ± 18 * 42 ± 17 * <0.001
Nuts, g/day 15 ± 18 15 ± 17 0.293 5 ± 7 * 32 ± 24 * <0.001 9 ± 12 * 33 ± 20 * <0.001 11 ± 16 * 18 ± 19 * <0.001
Total fish, g/day 100 ± 49 101 ± 49 0.243 105 ± 51 * 101 ± 47 * 0.002 102 ± 51 * 105 ± 46 * <0.001 50 ± 23 * 162 ± 37 * <0.001
Total cereals, g/day 135 ± 74 * 163 ± 80 * <0.001 191 ± 90 * 138 ± 70 * <0.001 213 ± 88 * 128 ± 68 * <0.001 145 ± 81 152 ± 75 0.140
Dairy products, g/day 322 ± 213 * 388 ± 204 * <0.001 411 ± 225 * 326 ± 196 * <0.001 391 ± 222 * 329 ± 199 * <0.001 353 ± 214 349 ± 202 0.082
Total meat, g/day 112 ± 44 * 170 ± 63 * <0.001 156 ± 59 * 144 ± 58 * <0.001 161 ± 61 * 141 ± 57 * <0.001 128 ± 58 * 156 ± 60 * <0.001
Cookies, g/day 16 ± 24 * 43 ± 38 * <0.001 33 ± 38 * 27 ± 29 * <0.001 41 ± 41 * 21 ± 25 * <0.001 27 ± 32 * 24 ± 27 * 0.001
Alcohol, g/day 7 ± 12 * 13 ± 16 * <0.001 16 ± 19 * 9 ± 12 * <0.001 19 ± 21 * 7 ± 11 * <0.001 10 ± 15 * 11 ± 14 * 0.030
17-item MedDiet Q, score 9.82 ± 2.49 * 7.50 ± 2.59 * <0.001 7.97 ± 2.58 * 8.86 ± 2.76 * <0.001 7.67 ± 2.62 * 9.49 ± 2.59 * <0.001 7.64 ± 2.57 * 9.46 ± 2.59 * <0.001
Abbreviations: FA, fatty acids; MedDiet Q, Mediterranean Diet Questionnaire; MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; SFAs, saturated fatty acids. All
values are means ± SDs unless otherwise indicated. All quartiles were included in the analysis. Pearson’s chi-square test was used for categorical variables, and 1-factor ANOVA was used
for continuous variables. * p < 0.05 for between-group changes, after adjustment for multiple comparisons with the Bonferroni method. NS No statistical significance after post hoc test.
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Consumption of olive oil, nuts, total fish, and total meat increased significantly with increasing
quintiles of total dietary fat intake, whereas consumption of fruits, vegetables, legumes, total cereals,
dairy products, cookies, and alcohol decreased. Similar results were obtained when MUFA quintiles
were assessed. In contrast, participants in the highest quintile of PUFA intake had higher consumption
of vegetables and legumes but lower total meat consumption. Participants in the highest quintile of
ω-3 FA intake had higher consumption of fruits, vegetables, legumes, and total meat; and highest
quintile of ALA intake had higher consumption of vegetables but lower of fruits, legumes, total cereals
and olive oil, as well as meat. Otherwise, participants in the highest quintile of SFA intake had lower
consumption of fruits, vegetables, legumes, nuts, total fish, total cereals, and dairy products, but higher
consumption of total meat and cookies. Highest quintile of TFA intake was also associated with higher
consumption of total cereals, dairy products, total meat, cookies and alcohol but lower consumption of
fruits and vegetables. Overall, participants in the highest quintile of total and all subtypes of dietary
fat intake had a significantly higher MedDiet score, except for SFA and TFA intake.
Prevalence of hyperglycemia was significantly higher in the highest quintiles of total and all
subtypes of dietary fat intake except for TFA and ALA intake. Prevalence of low HDL-c was also higher
in participants with the highest quintile of total fat, PUFA and LA intake but lower in the highest
quintiles of ω-3 FA, MUFA, SFA, and TFA intake; and abdominal obesity prevalence was higher in
participants with the highest quintile of ALA intake. Contrarily, the prevalence of hypertriglyceridemia
was lower in participants with highω-3 FA intake. Hypertension prevalence did not differ significantly
according to intake of any type of fat.
Multivariate adjusted Odds Ratios (ORs) for components of the MetS across quintiles of total
dietary fat intake and several subtypes of dietary fat intake are presented in Table 4. After adjustment
for potential confounders (i.e., age, sex, BMI, smoking habit, education, energy, and alcohol intake,
adherence to the MedDiet and physical activity), the OR of hyperglycemia were 1.2–1.6 times higher
from the fourth-fifth quintile (Q4–Q5) of total fat and MUFA intakes compared with the first quintile;
the OR of hyperglycemia were 1.3–1.6 times higher from the third-fifth quintile (Q3–Q5) of SFA intake
compared with the first quintile. However, the OR forω-3 FA intake was 1.3 times higher only for the
fifth quintile (Q5) compared with the first quintile. The OR of low HDL-c was also 1.2 times higher for
the fifth quintile of LA compared with the first quintile. Contrarily, the OR of hypertriglyceridemia
were 0.7–0.8 times lower from the third quintiles (Q3–Q5) of SFA intake and the OR forω-3 FA intake
was 0.7 times lower only for the fifth quintile compared with the first quintiles.
Table 4. Association between total dietary fat and specific types of fat with the Metabolic Syndrome
components (as dichotomous variables).
Quintiles
p Value
1 2 3 4 5
Total fat
High blood pressure 1.00 (ref.) 0.99 (0.73, 1.35) 0.81 (0.61, 1.10) 0.96 (0.71, 1.30) 0.94 (0.69, 1.27) 0.615
Hyperglycemia 1.00 (ref.) 0.94 (0.78, 1.12) 1.13 (0,94, 1.36) 1.23 (1.02, 1.48) 1.55 (1.28, 1.88) <0.001
Hypertriglyceridemia 1.00 (ref.) 0.81 (0.69, 0.95) 0.88 (0.74, 1.03) 0.87 (0.74, 1.02) 0.90 (0.76, 1.06) 0.153
Low HDL-c 1.00 (ref.) 1.06 (0.90, 1.25) 1.19 (1.01, 1.40) 1.20 (1.02, 1.42) 1.14 (0.96, 1.34) 0.133
Abdominal obesity 1.00 (ref.) 1.19 (0.81, 1.75) 1.33 (0.90, 1.98) 1.60 (1.06, 2.43) 1.75 (1.15, 2.68) 0.065
MUFAs
High blood pressure 1.00 (ref.) 1.17 (0.86, 1.59) 0.99 (0.73, 1.33) 0.87 (0.65, 1.17) 0.97 (0.72, 1.31) 0.429
Hyperglycemia 1.00 (ref.) 0.97 (0.81, 1.16) 0.98 (0.81, 1.17) 1.26 (1.04, 1.52) 1.45 (1.19, 1.75) <0.001
Hypertriglyceridemia 1.00 (ref.) 0.93 (0.79, 1.09) 0.91 (0.78, 1.07) 0.99 (0.84, 1.16) 0.98 (0.83, 1.15) 0.741
Low HDL-c 1.00 (ref.) 1.07 (0.91, 1.26) 1.10 (0.94, 1.30) 1.18 (1.00, 1.38) 1.14 (0.97, 1.34) 0.359
Abdominal obesity 1.00 (ref.) 1.12 (0.76, 1.66) 1.08 (0.73, 1.60) 1.58 (1.04, 2.42) 1.54 (1.01, 3.34) 0.111
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Table 4. Cont.
Quintiles
p Value
1 2 3 4 5
PUFAs
High blood pressure 1.00 (ref.) 0.94 (0.69, 1.28) 0.89 (0.65, 1.20) 0.87 (0.64, 1.17) 0.93 (0.69, 1.27) 0.902
Hyperglycemia 1.00 (ref.) 1.02 (0.85, 1.23) 1.23 (1.02, 1.48) 1.23 (1.02, 1.49) 1.10 (0.91, 1.33) 0.084
Hypertriglyceridemia 1.00 (ref.) 1.10 (0.93, 1.29) 0.92 (0.78, 1.08) 1.12 (0.95, 1.33) 1.05 (0.89, 1.24) 0.105
Low HDL-c 1.00 (ref.) 0.96 (0.81, 1.13) 0.96 (0.82, 1.14) 1.11 (0.94, 1.31) 1.12 (0.95, 1.32) 0.160
Abdominal obesity 1.00 (ref.) 1.05 (0.70, 1.58) 1.13 (0.74, 1.71) 1.06 (0.71, 1.60) 1.31 (0.86, 2.00) 0.771
SFAs
High blood pressure 1.00 (ref.) 0.86 (0.64, 1.15) 1.10 (0.81, 1.50) 1.08 (0.80, 1.47) 0.95 (0.70, 1.28) 0.432
Hyperglycemia 1.00 (ref.) 1.17 (0.97, 1.41) 1.25 (1.04, 1.51) 1.35 (1.12, 1.63) 1.58 (1.31, 1.92) <0.001
Hypertriglyceridemia 1.00 (ref.) 0.96 (0.81, 1.13) 0.83 (0.71, 0.98) 0.85 (0.72, 1.00) 0.74 (0.63, 0.87) 0.003
Low HDL-c 1.00 (ref.) 1.12 (0.95, 1.32) 1.00 (0.84, 1.18) 1.12 (0.94, 1.32) 0.94 (0.79, 1.11) 0.137
Abdominal obesity 1.00 (ref.) 1.07 (0.72, 1.61) 1.40 (0.91, 2.16) 1.02 (0.68, 1.53) 1.33 (0.87, 2.02) 0.404
Trans FA
High blood pressure 1.00 (ref.) 0.97 (0.72, 1.30) 1.27 (0.92, 1.74) 0.87 (0.64, 1.18) 1.14 (0.81, 1.60) 0.114
Hyperglycemia 1.00 (ref.) 0.94 (0.78, 1.14) 1.17 (0.96, 1.43) 1.03 (0.84, 1.26) 1.12 (0.90, 1.38) 0.191
Hypertriglyceridemia 1.00 (ref.) 0.93 (0.79, 1.09) 0.93 (0.79, 1.10) 0.95 (0.80, 1.13) 0.81 (0.68, 0.98) 0.246
Low HDL-c 1.00 (ref.) 0.99 (0.84, 1.16) 1.02 (0.87, 1.21) 0.92 (0.78, 1.10) 0.89 (0.74, 1.07) 0.489
Abdominal obesity 1.00 (ref.) 1.68 (1.07, 2.64) 1.28 (0.84, 1.95) 1.34 (0.87, 2.07) 1.44 (0.91, 2.30) 0.256
Linoleic acid
High blood pressure 1.00 (ref.) 0.98 (0.72, 1.34) 0.77 (0.57, 1.04) 0.93 (0.68, 1.26) 0.91 (0.67, 1.23) 0.423
Hyperglycemia 1.00 (ref.) 1.08 (0.91, 1.32) 1.17 (0.97, 1.41) 1.24 (1.03, 1.50) 1.08 (0.90, 1.30) 0.222
Hypertriglyceridemia 1.00 (ref.) 1.00 (0.85, 1.18) 1.05 (0.89, 1.24) 1.14 (0.97, 1.35) 1.12 (0.95, 1.32) 0.354
Low HDL-c 1.00 (ref.) 0.90 (0.76, 1.06) 1.08 (0.91, 1.27) 1.14 (0.97, 1.34) 1.18 (1.00, 1.39) 0.009
Abdominal obesity 1.00 (ref.) 1.14 (0.75, 1.73) 1.11 (0.74, 1.69) 1.12 (0.75, 1.69) 1.19 (0.79, 1.79) 0.939
Linolenic acid
High blood pressure 1.00 (ref.) 0.83 (0.61, 1.13) 0.82 (0.59, 1.15) 0.99 (0.69, 1.40) 0.82 (0.59, 1.14) 0.488
Hyperglycemia 1.00 (ref.) 1.05 (0.86, 1.27) 1.17 (0.95, 1.44) 1.08 (0.87, 1.34) 1.03 (0.84, 1.26) 0.614
Hypertriglyceridemia 1.00 (ref.) 1.10 (0.92, 1.30) 1.12 (0.94, 1.35) 1.09 (0.91, 1.32) 1.05 (0.88, 1.26) 0.744
Low HDL-c 1.00 (ref.) 1.00 (0.84, 1.19) 0.97 (0.80, 1.16) 0.94 (0.78, 1.14) 1.04 (0.87, 1.25) 0.822
Abdominal obesity 1.00 (ref.) 1.54 (1.02, 2.33) 1.36 (0.87, 2.12) 1.20 (0.77, 1.89) 1.53 (0.98, 2.41) 0.219
ω-3 FA
High blood pressure 1.00 (ref.) 0.97 (0.73, 1.30) 1.45 (1.06, 1.99) 0.93 (0.69, 1.25) 1.03 (0.76, 1.40) 0.048
Hyperglycemia 1.00 (ref.) 1.13 (0.94, 1.36) 1.02 (0.85, 1.23) 1.08 (0.89, 1.30) 1.33 (1.09, 1.62) 0.036
Hypertriglyceridemia 1.00 (ref.) 0.86 (0.73, 1.02) 0.97 (0.82, 1.14) 0.91 (0.77, 1.08) 0.77 (0.65, 0.91) 0.016
Low HDL-c 1.00 (ref.) 0.91 (0.77, 1.07) 0.86 (0.73, 1.01) 0.97 (0.82, 1.14) 0.84 (0.71, 1.00) 0.175
Abdominal obesity 1.00 (ref.) 1.22 (0.81, 1.86) 1.05 (0.70, 1.57) 0.93 (0.62, 1.40) 1.50 (0.95, 2.38) 0.237
Abbreviations: CI, confidence interval; HDL-c, high density lipoprotein cholesterol; OR, odds ratio; ref., reference.
Values are expressed as n (%) and OR (95% CI). Logistic regression analysis comparing the presence of Metabolic
Syndrome and its components (independent variables) between quintiles of total dietary fat and specific types
(dependent variable). Logistic regression analysis after adjustment for sex, age (continuous variable), body mass
index (continuous variable), smoking habit (categorized variable), education (categorized variable), energy intake
(continuous variable), alcohol intake (continuous variable), adherence to the Mediterranean Diet (continuous
variable) and physical activity (continuous variable, expressed as MET·min/week).
4. Discussion
In this cross-sectional study we evaluated the association of total dietary fat and specific subtypes
of dietary fat intake with the components of MetS in a Mediterranean population at high cardiovascular
risk. The most important finding of the present study is a significant increase in the risk of hyperglycemia
among participants in the upper quintiles of total dietary fat, SFA, MUFA, andω-3 FA intake, a significant
increase in the risk of low HDL-c levels among participants in the upper quintile of LA, and a significant
decrease in the risk of hypertriglyceridemia among participants in the upper quintiles of SFA andω-3
FA intakes.
Controversial results in relation to hyperglycemia and dietary fat intake associations have been
observed in the literature. Our results are in accordance with those reporting that fat intake is
positively associated with the prevalence of impaired fasting glucose [34,35] and lately diagnosed
and undiagnosed T2DM [34,36,37]. Nevertheless, several studies did not highlight any association
between total fat intake and TD2M risk [38–42]. Therefore, dietary fats could affect insulin resistance
or risk of diabetes through several mechanisms. In the state of insulin resistance, lipogenesis is
inhibited and lipolysis is exalted in adipocytes, which increases concentrations of circulating fatty acids.
Consequently, typical dyslipidaemia is characterized by elevated TG, lowered HDL-C, and small and
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dense LDL-C particles, established as a risk factor for CVD, and associated with hyperinsulinaemia [43].
In the vascular-metabolic Clinica Universidad de Navarra (VM-CUN) cohort, the prediction ability of
triglyceride-glucose index (TyG index) and fasting plasma glucose was compared to predict incident
T2DM and reported that its predictive ability is better than that of the Homeostatic Model Assessment
for Insulin Resistance (HOMA-IR) [44]. Moreover, the higher level of TyG index was significantly
associated with an increased risk of incident T2DM [45] and developing CVD [46].
On the other hand, in our study high SFA intake and hyperglycemia were also positively associated.
A recent systematic review also pointed out positive associations between SFA intake and insulin
sensitivity in observational studies, but any association between SFA intake and incidence of T2DM
in prospective studies [47]. Another systematic review and meta-analysis of observational studies
did not found any association between SFA and T2DM [48]. The (Lipids, Genes and Metabolic
Syndrome Study (LIPGENE study) showed that MetS subjects responded differently to dietary fat
modification according to their homeostasis model assessment-insulin resistance (HOMA-IR) status.
Insulin-resistant MetS subjects with the highest HOMA-IR decreased fasting insulin and HOMA-IR
concentrations after consumption of a high MUFA (HMUFA) diet and high-complex carbohydrate
(LFHCC) diet supplemented with long-chain n-3 PUFA diet, and these decreases in the two markers
were significantly lower than with the high SFA (HSFA) diet. Conversely, fasting insulin and HOMA-IR
concentrations increased in the least insulin-resistant group after consumption of a high SFA (HSFA)
diet [49].
Our results also show a significant increase in the prevalence of hyperglycemia with increasing
MUFA andω-3 FA intake. However, our results could be attributed to lower consumption of fruits,
vegetables, legumes, fiber, and a higher meat intake among participants with the highest MUFA
intake but contrary to the participants with the lowestω-3 FA intake. A recent systematic review and
meta-analysis of randomized controlled feeding trials showed beneficial effects of MUFA and PUFA
on glucose-insulin homeostasis. Replacement of 5% dietary energy from carbohydrates or SFA with
5% dietary energy from either MUFA or PUFA lowered glycosylated hemoglobin A1C (HbA1c) and
HOMA-IR. Replacement of 5% dietary energy from carbohydrates, SFA, or MUFA with PUFA also
showed beneficial effects on insulin secretion ability [50]. Therefore, the modification of an individual
dietary pattern to regularly include foods rich in MUFA and PUFA, such as the MedDiet, can benefit
individuals with MetS and hyperglycemia or TD2M [51].
We also found that the OR for hypertriglyceridemia was lower in the upper quintiles of SFA intake
(Q3–Q5). Contrarily to our results, a positive association of SFA intake with serum TG has been found
in the literature [52–55]. Otherwise, a previous systematic review pointed out that the replacement
of 1% dietary energy from SFA with MUFA or PUFA lowered TG levels [56]. However, our results
could be attributed to the synergistic effect of high olive oil consumption (a healthy source of MUFA)
among participants with the highest SFA intake. However, other studies have not found significant
association between MUFA and MetS components, such as hypertriglyceridemia [52,57].
The present study also showed a significant increase in risk of hypertriglyceridemia in the
upper quintile of ω-3 FA intake. Accordingly, some studies have shown that the intake of ω-3 FA,
eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), be effective in reducing plasma TG
concentrations [47,52,58,59]. Other authors have also reported that low fat diets enriched with PUFA or
replaced by healthy sources of fats (fish, avocado, nuts, broccoli, thistle, olives, linseed, and canola oil,
etc.) or healthy sources of carbohydrates (whole grains, legumes, vegetables, and fruits) also decreased
TG levels [49,60–65].
A previous systematic review of clinical trials found that some studies have observed that various
conjugated linoleic acid (CLA) isomers, administered as supplements or CLA-enriched products,
decreases HDL-c [66]. Another systematic review pointed out an inverse association between LA
intake and CHD risk [67]. Recently, Yanai et al. [68] pointed out that TFA is significantly associated
with reduction of HDL-c and coronary risks, whereas MUFA, plant sterols and stanols intake (except
policosanol) may not affect HDL-c. Conversely, fish oils consumption, especially DHA consumption,
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may be favorably associated with HDL metabolism [68]. In our study, LA intake but not TFA was
significantly associated with low HDL-c levels.
It is also noting that no association between TFA intake and components of MetS was observed in
our population; perhaps it is due to the intake of this type of fat being low in the elderly Mediterranean
population, who consume low amounts of processed food [69]. However, the consumption of TFA has
been identified as an important and modifiable risk factor for CHD [70]. Emerging data suggest that
TFA is associated with all causes of mortality, total CHD, and CHD mortality, probably because of
higher levels of intake of industrial TFA (products of partial hydrogenation of vegetable oils) than
ruminant TFA (meats and dairy products of cows, sheep, and goats) [48].
Lately, abdominal obesity and HTN are not significantly associated with dietary fat intake,
although these results could be attributed to the high prevalence of both MetS components in our
population. However, another study showed a significant rise in the risk of abdominal obesity (OR
1.61, CI 1.23–2.13) and HTN (OR 1.39, CI 1.06–1.81) with increasing fat intake [35]. Moreover, findings
from the Food4Me study showed a strong association between fat intake (total fat, MUFA, and SFA)
and obesity risk [71], which in agreement with two Cochrane meta-analyses [70,72] comparing the
weight loss effects of a low fat diet with usual diet showed an effect size of −1.5 kg and was mirrored
by reductions in BMI (−0.5 kg/m2) and WC (−0.3 cm). Otherwise, a high-quality, moderately high-fat
eating pattern (especially unsaturated fatty acids: PUFA and MUFA) like the MedDiet may have
beneficial effects on BW and obesity [73]. A recent meta-analysis also provided evidence that high
MUFA diets, as well as the Dietary Approaches to Stop Hypertension (DASH) and Mediterranean diets,
and supplementation with ω-3 FA (EPA+DHA) effectively lowers blood pressure [47]. No evidence of
harmful effects of reducing SFA intakes on blood pressure has been observed in the literature [70].
Our results may help to highlight the fact that dietary recommendations should focus not on
lowering the total fat content of the diet but rather on specific types of fats and carbohydrates and,
more importantly, on specific foods and overall dietary patterns [9] for individuals at high CVD risk.
5. Strengths and Limitations
Our study also has various strengths. The large study sample is highly representative of Spanish
older adults with MetS (n = 6560), and the use of a standardized protocol reduces information bias
about food intake, socioeconomic and lifestyles variables. Some methodological limitations should
be acknowledged. First, the cross-sectional study nature; thus, causal inferences cannot be drawn.
Second, the FFQ, the source of information to assess dietary fat intake, could overestimate the intake of
certain food groups even having been validated. Third, we excluded participants with energy intake
out of predefined ranges, to avoid information bias [15]. Previously, in the PREDIMED study, 827
participants who had extreme values for total energy intake or any micronutrient intake out of the
predefined values were also excluded in the nutritional adequacy analysis [15]. Moreover, the present
findings cannot be extrapolated to other population groups given that our study participants are
senior adults with overweight/obesity and MetS. Although there have been controversies regarding the
criteria of MetS, the harmonizing worldwide criteria have been agreed on by international academic
societies [15]. However, some professional societies have pointed out the limitations of MetS as clinical
and epidemiologic too [74–76]. Finally, the overestimation of the prevalence ratios derived from the
OR when logistic regression is applied.
6. Conclusions
These data suggest a potential different role of types of dietary fat on the MetS components of
individuals at high cardiovascular risk. Our main findings suggest that the intake of dietary fat was
associated with a higher risk of hyperglycemia. It is likely that the effects of dietary fat intake on
cardiometabolic syndrome will be influenced by the combination of nutrients of the food consumed.
Therefore, the type of dietary fat should be considered for future dietary recommendations to decrease
risk of MetS at a population level.
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